Signova Pharma

Pharmaceutical product development and distribution in healthcare.

About Signova Pharma

Signova Pharma is a Healthcare company. Pharmaceutical product development and distribution in healthcare. The company has 421 employees. Its Indian entity Signova Pharma Private Limited reported revenue of β‚Ή131 Cr. Signova Pharma offers products and services including Rabsig DSR and Raxclav 625. Its focus areas include Pharmaceuticals, Drug Manufacturing, Generic Medications and Medical Supplies.

Company details

Signova Pharma has been established since January 2008, where consistent efforts are made to pursue excellence in healthcare services through the development of safe and efficacious products. The companys range is updated regularly with the latest molecules to foster a healthy society, as initiatives are taken for sustainable growth and a strong industry position. Valuable efforts are directed towards serving humanity and providing quality pharmaceutical offerings across 26 categories, ensuring multi-lateral growth is achieved without promotional emphasis.

Key Metrics
  • Indian entity revenue
    ₹131 Cr

    FY 2025 · 0% YoY

  • Indian entity net profit
    ₹6.79 Cr

    FY 2025 · 5% margin

  • Indian entity EBITDA
    ₹11.66 Cr

    FY 2025 · 9% margin

  • Employee Count
    421

Products & Services of Signova Pharma

Signova Pharma offers a comprehensive portfolio of products and services, including Rabsig DSR and Raxclav 625.

Rabsig DSR
Pharmaceutical Products

This product is provided as part of the company's range aimed at delivering safe and efficacious healthcare solutions.

Raxclav 625
Pharmaceutical Products

This product is included among the offerings that are updated with the latest molecules to support quality healthcare.

Board of directors of Signova Pharma Private Limited (Signova Pharma)

Signova Pharma Private Limited is the primary company behind Signova Pharma. The board of Signova Pharma Private Limited currently have 2 directors; the longest-serving is Satrajit Kanungo, appointed in 2008.

DirectorDesignationAppointedTenureEntity
Satrajit Kanungo
DIN 00005002
Director04 Jan 200818 yrs 10 moSignova Pharma Private Limited
Ranjan Kumar Deka
DIN 01157216
Director04 Jan 200818 yrs 10 moSignova Pharma Private Limited

Financials of Signova Pharma

Figures of Signova Pharma Private Limited, the primary company behind Signova Pharma, for FY 2025. Revenue was ₹131 Cr (0% year on year). Net profit was ₹6.79 Cr (5% margin). EBITDA was ₹11.66 Cr (9% margin). Revenue has grown at a compounded annual rate of +17% over three years and +16% over five years.

  • ₹131 CrRevenue · FY 2025 · 0% YoY
  • ₹6.79 CrNet profit · 5% margin
  • ₹11.66 CrEBITDA · 9% margin
  • ₹40 LakhPaid-up capital
  • 421Employees (provident fund records)
  • +17%Revenue CAGR, 3 years
  • +16%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Signova Pharma Private Limited are on its company page.

Premium access

Detailed financial statements for Signova Pharma

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Signova Pharma

Signova Pharma has 421 employees.

The primary company behind Signova Pharma, Signova Pharma Private Limited, reported revenue of β‚Ή131 Cr for FY 2025, down 0% year on year.

Signova Pharma has been established since January 2008, where consistent efforts are made to pursue excellence in healthcare services through the development of safe and efficacious products. The companys range is updated regularly with the latest molecules to foster a healthy society, as initiatives are taken for sustainable growth and a strong industry position. Valuable efforts are directed towards serving humanity and providing quality pharmaceutical offerings across 26 categories, ensuring multi-lateral growth is achieved without promotional emphasis.

Signova Pharma offers Rabsig DSR and Raxclav 625.

Signova Pharma operates through Signova Pharma Private Limited.

The legal entities of Signova Pharma currently have 2 directors, including Satrajit Kanungo, Ranjan Kumar Deka.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available